Formulary Support
Leverage resources below to help your health system integrate DefenCath seamlessly, from formulary inclusion to product ordering.
Find downloadable resources below.
DefenCath Prescribing Information
Download the Prescribing Information for DefenCath (taurolidine and heparin) catheter lock solution.
Formulary Fact Sheet
Download this fact sheet to use as a quick reference when filling out a formulary request form for DefenCath.
Agarwal A, et al. 2023 Clin J Am Soc Nephrol.
Download the Agarwal et al. publication from the Clinical Journal of the American Society of Nephrology.
FAQ Resource
Download this resource for details on frequently asked questions related to CRBSI’s and DefenCath (taurolidine and heparin) catheter lock solution.
DefenCath Product Ordering Sheet
Download this resource to help navigate the product ordering process.
Schedule an Appointment
Visit DefencathSupport.com to schedule an appointment with a reimbursement specialist.
CRBSI = catheter-related bloodstream infection.
Reference: 1. DefenCath (taurolidine and heparin) [prescribing information]. Berkeley Heights, NJ: CorMedix Inc; 2023.
Speak with a representative
Have questions about DefenCath? Open the form below to request a call with a representative.
Open formIMPORTANT SAFETY INFORMATION (cont'd)
CONTRAINDICATIONS
DefenCath is contraindicated in patients with:
- Known heparin-induced thrombocytopenia (HIT).
- Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DefenCath), or pork products.
WARNINGS AND PRECAUTIONS
- Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If HIT occurs, discontinue DefenCath and institute appropriate supportive measures.
- Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DefenCath and institute appropriate supportive measures.
ADVERSE REACTIONS
The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
Indications and Usage
LIMITED POPULATION: DefenCath® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Limitations of Use
The safety and effectiveness of DefenCath have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
Please see the full Prescribing Information.